All Stories

  1. Acknowledgement to Reviewers
  2. International consensus for the assessment of social cognition in neurocognitive disorders: framework definition and clinical recommendations of the SIGNATURE initiative
  3. The measurement of agitation in neurocognitive disorders: A systematic review
  4. Plasma biomarkers in neuropsychiatric syndromes: A narrative review
  5. Disentangling the Clinical and Neuroimaging Spectrum of Neuronal α-Synucleinopathies
  6. List of reviewers
  7. Atrophy patterns of deep gray matter nuclei in Alzheimer's disease and frontotemporal dementia
  8. The relationships between cerebrospinal fluid neurofilament light chain and hippocampal atrophy with cognitive decline
  9. Leveraging multiomic approaches to elucidate mechanisms of heterogeneity in Alzheimer's disease: Neuropsychiatric symptoms, co‐pathologies, and sex differences
  10. Message From the Editors to Our Reviewers
  11. International consensus for the assessment of social cognition in neurocognitive disorders: framework definition and clinical recommendations of the SIGNATURE initiative
  12. APOE -mediated associations of promoter variants of GRIN1 and GRIN2B with behavioral symptoms and age at onset of Alzheimer’s disease dementia
  13. Understanding barriers and optimizing socio‐cognitive assessment in the diagnosis of neurocognitive disorders
  14. Analysis and interpretation of inflammatory fluid markers in Alzheimer’s disease: a roadmap for standardization
  15. Message From the Editors to Our Reviewers
  16. The problem of multiple adjustments in the assessment of minimal clinically important differences
  17. Biomarkers in Clinical Trials of Alzheimer Disease: An Overview
  18. Associations between selected genetic variants and lipid profile variability in response to statins in Alzheimer’s disease: a prospective observational study
  19. List of Reviewers
  20. Anthropometric and Demographic Features Affect the Interpretation of Cerebrospinal Fluid Biomarkers in Patients with Different Dementia Syndromes and Cognitively Healthy Adults
  21. Considerations for widespread implementation of blood‐based biomarkers of Alzheimer's disease
  22. Recommendations for clinical implementation of blood‐based biomarkers for Alzheimer's disease
  23. Assessing Independence in Activities of Daily Living and Quality of Life in Patients with Dementia with Lewy Bodies
  24. Message From the Editors to Our Reviewers
  25. Shedding Light on the Effects of Blood Pressure on Cognitive Decline and Dementia Risk by Way of Neurobiological Evidence
  26. Biofluid Activity and Levels of the Angiotensin-converting Enzyme Are Surrogates for Diverse Cerebrospinal Fluid Amyloid-beta Effects in Dementia with Lewy Bodies and Alzheimer’s Dementia (P6-9.001)
  27. Message From the Editors to Our Reviewers
  28. Acknowledgement to Reviewers
  29. List of Reviewers
  30. GRIN2B genotypes and APOE haplotypes affect the age at onset of Alzheimer’s dementia as well as variations in dementia staging according to the use of Memantine
  31. Differential performance of cerebrospinal fluid biomarker ratios and formulas to discriminate dementia with Lewy bodies from Alzheimer’s dementia and cognitively healthy people reflects high level of amyloidosis across dementia syndromes
  32. Biofluid activity and levels of the angiotensin‐converting enzyme may translate into distinct neuropsychiatric symptoms associated with cerebrospinal fluid amyloid‐beta effects and tauopathy in dementia with Lewy bodies and Alzheimer’s dementia
  33. Disparities in neuropsychiatric symptom clusters across dementia diagnoses within Lewy body dementia syndromes and Alzheimer’s dementia
  34. Variations in metabolic risk factors for dementia do not affect APOE‐mediated cognitive or functional decline in patients with Alzheimer’s disease from São Paulo, Brazil
  35. Pitfalls and biases in neuroepidemiological studies of COVID-19 and the nervous system: a critical appraisal of the current evidence and future directions
  36. Pharmacogenetics of angiotensin modulators according to APOE-ε4 alleles and the ACE insertion/deletion polymorphism in Alzheimer’s disease
  37. Message From the Editors to Our Reviewers
  38. Looking Behind the Curtain: Patient Stratification According to Genetic or Demographic Factors May Yield Unexpected Results in Studies of Neurodegenerative Diseases
  39. Effects of the DICE Method to Improve Timely Recognition and Treatment of Neuropsychiatric Symptoms in Early Alzheimer’s Disease at the Memory Clinic: The BEAT-IT Study
  40. Differential associations of clinical features with cerebrospinal fluid biomarkers in dementia with Lewy bodies and Alzheimer’s disease
  41. Lifestyle and pharmacological interventions in South America: Potential barriers for recruitment, implementation, and effectiveness
  42. Acknowledgement to Reviewers
  43. Message From the Editors to Our Reviewers
  44. List of Reviewers
  45. The Advisory Group on Risk Evidence Education for Dementia: Multidisciplinary and Open to All
  46. Acknowledgement to Referees
  47. Acknowledgement
  48. APOE ε4 Carrier Status as Mediator of Effects of Psychotropic Drugs on Clinical Changes in Patients With Alzheimer’s Disease
  49. Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions
  50. Message From the Editors to Our Reviewers
  51. Pharmacogenetic Analyses of Therapeutic Effects of Lipophilic Statins on Cognitive and Functional Changes in Alzheimer’s Disease
  52. New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia
  53. The Viability of Treatment Conditioned to the Pathophysiology of Alzheimer’s Disease
  54. Vascular cognitive impairment and dementia: An early career researcher perspective
  55. Message From the Editors to Our Reviewers
  56. List of Reviewers
  57. Acknowledgement
  58. Reviewer Acknowledgement, 2021
  59. Message From the Editors to Our Reviewers
  60. Associations of Neuropsychiatric Features with Cerebrospinal Fluid Biomarkers of Amyloidogenesis and Neurodegeneration in Dementia with Lewy Bodies Compared with Alzheimer’s Disease and Cognitively Healthy People
  61. Abstract Anne H Berman – incoming ISBM president
  62. Behavioural effects of the ACE insertion/deletion polymorphism in Alzheimer’s disease depend upon stratification according to APOE-ϵ4 carrier status
  63. Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe
  64. APOE-ɛ4-mediated correlates of cerebrospinal fluid biomarkers of amyloidosis and neurodegeneration with cognition and functionality in dementia with Lewy bodies compared with Alzheimer’s dementia and cognitively healthy people (49)
  65. Acknowledgements to Reviewers
  66. Swallowing in behavioral variant frontotemporal dementia
  67. Message From the Editors to Our Reviewers
  68. List of Reviewers
  69. Klüver‐Bucy syndrome due to stroke in the left temporal lobe
  70. Vascular cognitive impairment due to dilated perivascular spaces in putamen: Connections with the ventrolateral prefrontal cortex and neurological deficits
  71. Dementia in Latin America: Paving the way toward a regional action plan
  72. Correlates of neuropsychiatric and motor tests with language assessment in patients with Lewy body dementia
  73. Selected LDLR and APOE Polymorphisms Affect Cognitive and Functional Response to Lipophilic Statins in Alzheimer’s Disease
  74. Neuropsychiatric feature profiles of patients with Lewy body dementia
  75. Agitation and impulsivity in mid and late life as possible risk markers for incident dementia
  76. The impact of SARS‐CoV‐2 in dementia across Latin America: A call for an urgent regional plan and coordinated response
  77. Acknowledgments
  78. CEREBROSPINAL-FLUID-BASED BIOMARKER EVIDENCE OF AMYLOIDOGENESIS IN DEMENTIA WITH LEWY BODIES DEPENDS UPON APOE-ε4 CARRIER STATUS
  79. PRISON WITHOUT WALLS: A CASE REPORT OF SEMANTIC VARIANT PRIMARY PROGRESSIVE APHASIA
  80. GRIN2A GENOTYPES AND APOE HAPLOTYPES AFFECT THE AGE AT ONSET OF ALZHEIMER’S DEMENTIA BUT NOT FUNCTIONAL OR COGNITIVE RESPONSE TO MEMANTINE
  81. FOOT CLEARANCE WHILE STEPPING-IN-PLACE AS A TOOL TO SALIENT COGNITIVE AND MOTOR OUTPUT DEFICITS IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT: A PRELIMINARY STUDY
  82. BEHAVIORAL CORRELATES OF CEREBROSPINAL FLUID BIOMARKERS ACCORDING TO APOE-ε4 CARRIER STATUS IN DEMENTIA WITH LEWY BODIES COMPARED WITH ALZHEIMER’S DEMENTIA AND COGNITIVELY HEALTHY PEOPLE
  83. Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia
  84. Acknowledgements to Reviewers
  85. Acknowledgments
  86. Influence of Socioeconomic Status and Stress Over Quality of Sleep: A Systematic Review
  87. Author Index
  88. Keyword Index
  89. Movement Disorders: Volume 33, Number S2, October 2018
  90. Abstracts
  91. Lifetime Risk Factors for Functional and Cognitive Outcomes in Patients with Alzheimer’s Disease
  92. GENETICALLY MEDIATED LIFETIME RISK FACTORS FOR COGNITIVE AND FUNCTIONAL DECLINE IN PATIENTS WITH ALZHEIMER’S DEMENTIA FROM SÃO PAULO, BRAZIL
  93. APOE-DEPENDENT PSYCHOTROPIC EFFECTS OVER CLINICAL CHANGES IN ALZHEIMER’S DISEASE DEMENTIA
  94. COGNITIVE AND FUNCTIONAL CORRELATES OF CEREBROSPINAL FLUID CONCENTRATIONS OF AMINOACIDS AND MONOAMINE METABOLITES ACCORDING TO APOE-ε4 CARRIER STATUS IN DEMENTIA WITH LEWY BODIES COMPARED WITH ALZHEIMER’S DEMENTIA AND COGNITIVELY HEALTHY PEOPLE
  95. COGNITIVE CHANGES ARE PHARMACOGENETICALLY MEDIATED BY ANGIOTENSIN-CONVERTING ENZYME INHIBITORS IN PATIENTS WITH ALZHEIMER’S DISEASE DEMENTIA
  96. Behavioral correlates of cerebrospinal fluid concentrations of aminoacids and monoamine metabolites according to APOE-ɛ4 carrier status in dementia with Lewy bodies compared with Alzheimer’s dementia and cognitively healthy people (P4.190)
  97. Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia
  98. Acknowledgement to reviewers
  99. Effects of APOE haplotypes and measures of cardiovascular risk over gender-dependent cognitive and functional changes in one year in Alzheimer's disease
  100. Acknowledgements to Reviewers
  101. ePresentation
  102. ePoster Session
  103. Author Index
  104. Issue Information
  105. Associations of cerebrovascular metabolism genotypes with neuropsychiatric symptoms and age at onset of Alzheimer’s disease dementia
  106. Longitudinal lipid profile variations and clinical change in Alzheimer's disease dementia
  107. Reviewers for International Journal of Stroke 2016
  108. Neurological impressions on the organization of language networks in the human brain
  109. GRIN1 GENOTYPES AND APOE GENE HAPLOTYPES AFFECT THE AGE AT ONSET OF ALZHEIMER'S DISEASE DEMENTIA BUT NOT COGNITIVE OR FUNCTIONAL RESPONSE TO MEMANTINE
  110. EFFECTS OF APOE GENE HAPLOTYPES AND MEASURES OF CARDIOVASCULAR RISK OVER COGNITIVE AND FUNCTIONAL DECLINE IN ONE YEAR IN PATIENTS WITH ALZHEIMER'S DISEASE DEMENTIA
  111. MOTOR ASPECTS OF DAILY LIVING FOLLOW COGNITIVE AND FUNCTIONAL STATUS BUT NOT BEHAVIOURAL SYMPTOMS IN PATIENTS WITH LEWY BODY DEMENTIA SYNDROMES
  112. Balance impairment does not necessarily coexist with gait apraxia in mild and moderate Alzheimer’s disease
  113. Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea and creatinine variations in patients with dementia due to Alzheimer disease
  114. Swallowing in primary progressive aphasia
  115. Predictors of Cognitive and Functional Decline in Patients With Alzheimer Disease Dementia From Brazil
  116. Associations of Blood Pressure with Functional and Cognitive Changes in Patients with Alzheimer's Disease
  117. The Controversial Influence of Cerebrovascular Risk Factors over Pathological Mechanisms of Late-Onset Alzheimer's Disease Dementia
  118. Risk factors for cognitive and functional change in one year in patients with Alzheimer's disease dementia from São Paulo, Brazil
  119. Correlations among cognitive and behavioural assessments in patients with dementia due to Alzheimer's disease
  120. Contrasts Between Patients With Lewy Body Dementia Syndromes and APOE-ε3/ε3 Patients With Late-onset Alzheimer Disease Dementia
  121. A patient with agrammatic primary progressive aphasia developing frontotemporal dementia
  122. Pharmacogenetics of cerebrovascular metabolism modulators in dementia due to Alzheimer’s disease
  123. Assessment of sleep satisfaction in patients with dementia due to Alzheimer’s disease
  124. Acknowledgements
  125. Is there correlation between cognition and functionality in severe dementia? The value of a performance-based ecological assessment for Alzheimer’s disease
  126. Brain-Penetrating Angiotensin-Converting Enzyme Inhibitors and Cognitive Change in Patients with Dementia due to Alzheimer's Disease
  127. P2‐024: PHARMACOGENETICS OF BRAIN‐PENETRATING ANGIOTENSIN‐CONVERTING ENZYME INHIBITORS IN DEMENTIA DUE TO ALZHEIMER'S DISEASE
  128. P2‐025: PHARMACOGENETICS OF CHOLESTEROL‐LOWERING DRUGS IN PATIENTS WITH DEMENTIA DUE TO ALZHEIMER'S DISEASE
  129. P3‐333: RISK FACTORS FOR COGNITIVE CHANGE IN PATIENTS WITH DEMENTIA DUE TO ALZHEIMER'S DISEASE FROM SÃO PAULO, BRAZIL
  130. Caregiver awareness of cerebrovascular risk of patients with dementia due to Alzheimer's disease in São Paulo, Brazil
  131. Abstracts from the 29th CINP World Congress of Neuropsychopharmacology, Vancouver, Canada, 22–26 June 2014
  132. Risk Factors for Cognitive Change in Patients with Dementia Due to Alzheimer’s Disease (P5.210)
  133. Pharmacogenetics of Lipid Metabolism Modulators in Patients with Dementia Due to Alzheimer’s Disease (P5.223)
  134. Risk factors for age at onset of dementia due to Alzheimer's disease in a sample of patients with low mean schooling from São Paulo, Brazil
  135. 2013 Reviewer Acknowledgement
  136. Assessment of risk factors for earlier onset of sporadic Alzheimer′s disease dementia
  137. Educational bias in the assessment of severe dementia: Brazilian cutoffs for severe Mini-Mental State Examination
  138. Pharmacological modulation of cognitive and behavioral symptoms in patients with dementia due to Alzheimer's disease
  139. Cognitive Impairment in Fibromyalgia
  140. Impact of Cardiovascular Risk over the Rate of Progression of Dementia Due to Alzheimer's Disease in a Sample of Patients with Low Schooling from São Paulo, Brazil (IN6-1.009)
  141. Impact of Cardiovascular Risk over the Rate of Progression of Dementia Due to Alzheimer's Disease in a Sample of Patients with Low Schooling from São Paulo, Brazil (P07.136)
  142. Communicating with the non-dominant hemisphere: Implications for neurological rehabilitation
  143. Normal pressure hydrocephalus in the spectrum of neurological complications of systemic lupus erythematosus
  144. A patient with primary progressive aphasia developing dementia due to Alzheimer's disease
  145. Impact of Cerebrovascular Risk Factors over Age of Onset of Dementia Due to Alzheimer's Disease in a Sample of Patients with Low Schooling from Sao Paulo, Brazil (P04.201)
  146. 2012 Annual Meeting Sunday, October 7, 2012 Poster Session Abstracts
  147. A topographic study on the evaluation of speech and language in the acute phase of a first stroke
  148. P1‐453: Functional independence and tests of cognitive assessment in patients with Alzheimer's disease
  149. P2‐153: Impact of cardiovascular risk factors over age of Alzheimer's disease onset in patients with low schooling
  150. P3‐260: Impact of schooling and cardiovascular risk factors over the rate of progression of Alzheimer's disease
  151. Twenty-first Meeting of the European Neurological Society 28–31 May, 2011
  152. Global aphasia as a predictor of mortality in the acute phase of a first stroke
  153. Semantic aphasia as a sole manifestation of acute stroke
  154. Preliminary topographic diagnosis of ischemic brain injuries according to speech and language disorders
  155. Short-term prognosis for speech and language in first stroke patients
  156. Hypoglossal nerve palsy as the sole manifestation of spontaneous internal carotid artery dissection
  157. Author Index
  158. Abstracts
  159. 0661 Primitive Neuroectodermal Tumor of the brain presenting with late spinal cord dissemination after surgical treatment and complementary radiotherapy and chemotherapy
  160. 1499 Trends on the use of complementary exams in modern day neurology: how to teach the patient about the tools actually needed for the investigation without conflicting knowledge with popular wisdom